Species: Human
Category: Cancer
Tissue of Origin: Brain
Cancer Type: Glioblastoma
Description
TS603 is a human brain cancer cell line.
Source
This cell line was established from a brain metastasis in a person with glioblastoma.
Lead Researcher/Research Laboratory
- Cameron W. Brennan, MD, Laboratory Head, Memorial Hospital Research, Memorial Sloan Kettering Cancer Center
- Ingo Mellinghoff, MD, FACP, Chair, Department of Neurology; Chief Brain Tumor Service, Evnin Family Chair in Neuro-Oncology, MSKCC
Key References
Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4. PMID: 23558169; PMCID: PMC3985613.
Licensing Information
This cell line may be licensed nonexclusively for research or commercial purposes.
- Express License: For internal research purposes by a for-profit entity: Fill out MSK’s Core Express License; see here for links to the online fillable Core Express License, as well as a PDF version. For detailed guidance on how to fill out this webform, see here. Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
- Commercial License: Contact MSK’s Tangible Research Materials team at TRMOTDRTM@mskcc.org.
- For non-licensing requests from academic-research institutions: Contact MSK’s Antibody & Bioresource Core Facility at skiabcf@mskcc.org.